Kintor reported Phase 2 topline data (180 male AGA patients, QD and BIW dosing arms) showing statistically significant hair-count gains vs placebo, and said it plans to start a Phase 2b/3 trial in China.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Topical first-in-class androgen receptor PROTAC (proteolysis-targeting chimera) that degrades the androgen receptor locally in scalp skin rather than just blocking it.
Results so far
0.5% QD arm: +16.80 hairs/cm2; 1% BIW arm: +11.94 hairs/cm2, both significant vs placebo; adverse event rate comparable to placebo with no reported adverse sexual events (press-release data).
What's next
Phase 2b/3 initiation in China targeted for 2026 per company statements; no global/FDA timeline given.
In India
No India-specific development identified.
Sources
- News report ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.